Rubicon Organics Inc (TSE:ROMJ)
:ROMJ
Top Page
Rubicon Organics
(ROMJ)
Select Model
Select Model
Rating:65Neutral
Price Target:
C$0.51
▲(8.72% Upside)
Action:ReiteratedDate:03/25/26
The score is driven primarily by improving operating performance and a strengthened balance sheet, tempered by weak current cash flow conversion (negative TTM operating and free cash flow) and only modest technical momentum. Valuation is a notable positive due to the very low P/E.
Positive Factors
Multi-year revenue growth and scale
Sustained multi-year revenue growth to ~59.5M TTM indicates the company has scaled distribution and product acceptance. Greater scale supports fixed-cost absorption, stronger negotiating leverage with provincial channels, and a more durable base to invest in premium brands and operations.
Negative Factors
Weak cash conversion
Negative operating and free cash flow despite reported net income signals earnings quality and working-capital challenges. Persistent cash deficits raise funding risk, may force external financing or capex delays, and constrain ability to self-fund growth or weather inventory cycles over months ahead.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth and scale
Sustained multi-year revenue growth to ~59.5M TTM indicates the company has scaled distribution and product acceptance. Greater scale supports fixed-cost absorption, stronger negotiating leverage with provincial channels, and a more durable base to invest in premium brands and operations.
Read all positive factors
Rubicon Organics (ROMJ) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$34.93M
Dividend YieldN/A
Average Volume (3M)65.53K
Price to Earnings (P/E)29.8
Beta (1Y)-0.10
Revenue Growth28.55%
EPS GrowthN/A
CountryCA
Employees208
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding67,175,770
10 Day Avg. Volume72,944
30 Day Avg. Volume65,526
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)0.71
Price to Sales (P/S)0.53
P/FCF Ratio-2.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.15Price Target Upside144.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)C$72.09M
Rubicon Organics Business Overview & Revenue Model
Company Description
Rubicon Organics Inc. (ROMJ) is a Canadian cannabis company focused on the cultivation, production, and distribution of premium organic cannabis products. Operating in the legal cannabis sector, Rubicon Organics is dedicated to sustainable farming...
How the Company Makes Money
Rubicon Organics makes money primarily by selling regulated cannabis products into the Canadian adult-use (recreational) market. Its core revenue stream is wholesale and/or direct-to-board sales of packaged cannabis (notably dried flower, and othe...
Rubicon Organics Earnings Call Summary
Earnings Call Date:Aug 18, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Jun 03, 2026
Earnings Call Sentiment Positive
Rubicon Organics demonstrated strong performance in Q2 2025 with record-breaking revenue growth, improved gross margins, and positive cash flow. Strategic expansion and innovation in product offerings indicate a solid position for future growth. However, the company faces challenges with share erosion in topicals, licensing delays for a new facility, and inventory management.Positive Updates
Record-Breaking Revenue and Growth
Rubicon Organics delivered a record net revenue of $15 million in Q2 2025, marking the highest ever for a single quarter, up 24% year-over-year and 21% sequentially.
Negative Updates
Share Erosion in Topicals
Experienced some share erosion in the topical category with competitors entering the market with more SKUs at lower price points.
Read all updates
Q2-2025 Updates
Positive
Negative
Record-Breaking Revenue and Growth
Rubicon Organics delivered a record net revenue of $15 million in Q2 2025, marking the highest ever for a single quarter, up 24% year-over-year and 21% sequentially.
Read all positive updates
Company Guidance
During Rubicon Organics' Q2 2025 earnings call, the company reported record net revenue of $15 million, marking a 24% increase year-over-year and a 21% sequential rise. Gross profit reached $5.9 million with a gross margin of 34%, up from 30% the previous year. Adjusted EBITDA was $1.4 million, contributing to a year-to-date total of $2.1 million. The company's growth was driven by its expanding 1964 brand, particularly in the pre-roll and vape segments, which saw a significant increase in SKUs and captured over 15% of the market. Rubicon also maintained a strong presence in premium edibles and topicals, holding the #1 position in premium edibles and #2 in topicals. The company completed a $4.5 million private placement and finalized the acquisition of its Hope facility to increase production capacity by 40%, positioning itself for further growth amid a global cannabis supply shortage. Rubicon closed the quarter with $7.3 million in cash and $18.7 million in working capital, supported by disciplined cost control and a prudent capital structure.Rubicon Organics Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
78
Positive
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 59.45M | 48.70M | 40.12M | 35.52M | 22.61M |
| Gross Profit | -6.79M | 15.42M | 13.14M | 13.81M | 1.51M |
| EBITDA | -15.33M | 1.86M | 1.95M | 217.00K | -10.87M |
| Net Income | 1.05M | -2.56M | -1.82M | -3.86M | -14.52M |
Balance Sheet | |||||
| Total Assets | 66.89M | 56.61M | 54.89M | 56.11M | 54.84M |
| Cash, Cash Equivalents and Short-Term Investments | 3.99M | 9.86M | 10.91M | 8.29M | 11.58M |
| Total Debt | 12.42M | 9.89M | 10.40M | 10.22M | 9.82M |
| Total Liabilities | 22.84M | 19.21M | 17.00M | 17.77M | 15.94M |
| Stockholders Equity | 44.06M | 37.40M | 37.89M | 38.33M | 38.90M |
Cash Flow | |||||
| Free Cash Flow | -12.04M | 1.85M | 2.32M | -2.50M | -15.94M |
| Operating Cash Flow | -3.63M | 3.40M | 5.05M | 1.95M | -10.44M |
| Investing Cash Flow | -8.42M | -1.55M | -2.73M | -4.45M | -5.50M |
| Financing Cash Flow | 6.25M | -1.77M | -804.01K | -838.56K | 15.30M |
Rubicon Organics Technical Analysis
Positive
0.47
Price Trends
0.47
Positive
0.48
Positive
0.50
Negative
Market Momentum
<0.01
Positive
55.43
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ROMJ, the sentiment is Positive. The current price of 0.47 is below the 20-day moving average (MA) of 0.49, below the 50-day MA of 0.47, and below the 200-day MA of 0.50, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.43 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ROMJ.
Rubicon Organics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$34.93M | 29.79 | 7.78% | ― | 28.55% | ― | |
61 Neutral | C$8.44M | 8.94 | 11.57% | ― | -1.14% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$29.96M | -19.43 | -71.80% | ― | -3.94% | -17.62% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
45 Neutral | C$8.46M | 5.19 | ― | ― | 15.64% | 58.47% |
* Healthcare Sector Average
TSE:ROMJ
Rubicon Organics
0.52
-0.01
-1.89%
TSE:LABS
MediPharm Labs
0.07
-0.03
-31.58%
TSE:PCLO
PharmaCielo
0.06
>-0.01
-8.33%
TSE:OILS
Nextleaf Solutions
0.05
0.00
0.00%
TSE:AVCN
Avicanna
0.15
-0.10
-40.00%
TSE:INNO
InnoCan Pharma
6.66
-5.04
-43.08%
Rubicon Organics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Rubicon Organics Posts Record 2025 Results and Scales Up Premium Cannabis Capacity
Positive
Mar 24, 2026
Rubicon Organics reported record 2025 net revenue of $59.5 million, up 22% year over year, with adjusted EBITDA rising to $5.0 million and operations turning from a loss to a $1.8 million profit. The company strengthened its balance sheet with new...
Business Operations and StrategyFinancial Disclosures
Rubicon Organics Delivers Record 2025 Results and Ramps Up Cascadia Facility
Positive
Mar 24, 2026
Rubicon Organics reported record 2025 net revenue of $59.5 million, up 22% from 2024, with gross profit before fair value adjustments rising 27% to $19.5 million and adjusted EBITDA reaching $5.0 million. The company generated $1.8 million in inco...
Business Operations and StrategyFinancial Disclosures
Rubicon Organics Sets Date to Report Q4 2025 Results Amid Capacity Expansion
Positive
Mar 10, 2026
Rubicon Organics will release its financial results for the fourth quarter and full year ended December 31, 2025 after markets close on March 23, 2026, followed by a conference call and webcast the next day to discuss its performance. The timing o...
Business Operations and Strategy
Rubicon Organics Boosts Premium Cannabis Output with Cascadia Facility Launch
Positive
Feb 19, 2026
Rubicon Organics has completed the first harvest at its new Cascadia facility in Hope, B.C., marking a key operational milestone in expanding its premium cannabis production base. The 47,500-square-foot indoor site is fully planted and is estimate...
Business Operations and StrategyExecutive/Board Changes
Rubicon Organics Grants Over 2 Million Equity Awards to Staff Under Incentive Plan
Positive
Jan 16, 2026
Rubicon Organics has awarded 1,002,773 restricted share units and 1,002,773 performance share units to selected executives and employees under its Omnibus Equity Incentive Plan, with RSUs vesting over one to three years and PSUs vesting after thre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.